FDA Approves First Vaccine to Prevent Serogroup B Meningococcal Disease

October 29, 2014 6:41 PM

3 0

The Food and Drug Administration (FDA) announced today the approval of Trumenba, the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.

Meningococcal disease is a life-threatening illness caused by bacteria that infect the bloodstream (sepsis) and the lining that surrounds the brain and spinal cord (meningitis). N. meningitidis is a leading cause of bacterial meningitis. The bacteria are transmitted from person to person through res...

Read more

To category page